La Jolla Pharmaceutical (LJPC) News Today → Only a fool would buy Nvidia today… (From Porter & Company) (Ad) Free ljpc Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineLa Jolla small business owners want lawful path to conduct business on the beachmsn.com - March 27 at 1:40 PMScripps Green Hospitalhealth.usnews.com - December 19 at 11:27 PMLa Jolla Pharmaceutical (NASDAQ: LJPC)fool.com - September 25 at 7:30 PMHepatorenal Syndrome Treatment Global Market Report 2023finance.yahoo.com - July 27 at 2:22 AMThalassemia Market Research | 2023-2030marketwatch.com - May 16 at 8:59 AMResults from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet ...businesswire.com - May 11 at 8:36 PMKidney (Renal) Fibrosis Market Report | Research Across The World 2031marketwatch.com - May 10 at 10:18 AMKidney Fibrosis Treatment Market Dynamics and Drivers: 2023-2031marketwatch.com - May 8 at 12:20 AMBased on recent market research, the Kidney/Renal Fibrosis Treatment market is set to experience robust growth, with a CAGR of 7% from 2023 to 2030.marketwatch.com - May 5 at 9:20 PMFibrodysplasia Ossificans Progressiva Drug Market Historical Trends and Future Prospect till 2031marketwatch.com - May 4 at 1:46 PMLa Jolla High Schoolusnews.com - May 3 at 10:44 PMCan The Proposed Antibiotic For Multidrug-Resistant Infections Fuel Innoviva's Revenue Growth?markets.businessinsider.com - April 19 at 1:55 PMThalassemia Market Complete Overview till 2030marketwatch.com - April 8 at 10:21 AMKidney Fibrosis Treatment Market-An Exclusive Study On Upcoming Trends And Growth Opportunities From 2023-2030marketwatch.com - April 7 at 8:37 AMKidney/Renal Fibrosis Treatment Market Size By 2031marketwatch.com - April 6 at 7:35 AMGlobal Thalassemia Market Size 2023 to 2026 Size and Share Survey Reportmarketwatch.com - March 27 at 6:20 PMKidney Fibrosis Treatment Market Major Players, Anlysis and Forecast till 2031marketwatch.com - March 22 at 6:36 PMKidney/Renal Fibrosis Treatment Market Analysis 2023-2028, Newly Upgraded Reportmarketwatch.com - March 20 at 8:53 AMScripps La Jolla Hospitalshealth.usnews.com - March 18 at 6:18 PMFibrodysplasia Ossificans Progressiva Drug Market Share, Segmentation and Forecast 2023-2028marketwatch.com - March 17 at 8:54 PMGlobal Fibrodysplasia Ossificans Progressiva Drug Market Size by Application (Hospital, Clinic, Research Center) Forecast from 2023 to 2028marketwatch.com - March 17 at 3:54 PMHeavy Metal Poisoning Drugs Market Size 2023 Research Report by Growth Rate Analysis and Forecast till 2027marketwatch.com - March 15 at 9:29 PMFibrodysplasia Ossificans Progressiva Drug Market Research Report 2023-2028 with Top Countries Datamarketwatch.com - March 13 at 10:22 PMGlobal Thalassemia Market Growth Prospects, Geography, Drivers, and Restraints 2023 – 2030 By VMReportsmarketwatch.com - March 12 at 6:36 PMKidney (Renal) Fibrosis Market Potential Analysis, by Trending Growth and CAGR 2023 to 2028marketwatch.com - March 10 at 8:10 AMUC San Diego Health-La Jolla and Hillcrest Hospitalshealth.usnews.com - February 25 at 9:33 AMKidney Fibrosis Treatment Market Size 2023 : Emerging Technologies, Opportunity and Forecast to 2028marketwatch.com - February 18 at 1:58 PMFibrodysplasia Ossificans Progressiva Drug Market is Booming in Near Future 2023-2028marketwatch.com - February 16 at 12:09 AMKidney Fibrosis Treatment Market (New Report) to Witness A Pronounce Growth During 2023-2029marketwatch.com - February 15 at 9:08 AMJohnson & Johnson Appoints Dr. John Reed as Executive Vice President, Pharmaceuticals, R&Dbenzinga.com - February 13 at 7:26 PMThalassemia Market Growth and Status Explored in a New Research Report 2028marketwatch.com - February 9 at 4:20 AMLa Jolla, United States - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - February 8 at 5:26 PMKidney Fibrosis Treatment Market is booming in near Future 2023-2028marketwatch.com - January 20 at 8:30 AMKidney (Renal) Fibrosis Market 2023 : Detailed Analysis of Industry, Potential Growth, Attractive Valuation and Growth Forecast Up to 2028marketwatch.com - January 10 at 8:57 AMLa Jolla Covetravel.usnews.com - December 31 at 7:28 PMKidney (Renal) Fibrosis Market Size 2023 : Segment Overview, Company Profiles, Regional Analysis and Forecast 2028marketwatch.com - December 17 at 6:30 PMThis market report on Vasopressin for Vasoplegic Shock provides broad description of this industry.marketwatch.com - December 9 at 4:05 PMKidney (Renal) Fibrosis Market 2022 : Advance Technology, Latest Trend and Future Expansion by 2028 | 107 Pages Reportmarketwatch.com - October 18 at 6:51 AMEverest Medicines Announces Approval of XERAVA® in Hong Kong for the Treatment of Complicated Intra-Abdominal Infectionsmarkets.businessinsider.com - October 7 at 10:15 PMLJPC Dec 2022 5.000 call(CONTRAfinance.yahoo.com - September 2 at 7:59 PMmarketbeat.com - August 22 at 6:05 AMLa Jolla Pharmaceutical (NASDAQ:LJPC) Upgraded at StockNews.commarketbeat.com - August 17 at 11:05 PMEverest Medicines Announces Regulatory Update and Strategic Partnership for Xerava™ in Taiwanmarkets.businessinsider.com - August 11 at 2:39 AMLa Jolla Pharmaceutical (NASDAQ:LJPC) Upgraded to "C-" by TheStreetmarketbeat.com - August 2 at 7:08 AMLa Jolla Pharmaceutical Co Stock Newsmorningstar.com - July 28 at 6:41 PMEquity Alert - The M&A Class Action Firm Announces the Investigation of La Jolla Pharmaceutical Co. - LJPCbenzinga.com - July 16 at 7:29 AMEquity Alert - The M&A Class Action Firm Announces the Investigation of La Jolla Pharmaceutical Co. - LJPCprnewswire.com - July 16 at 2:22 AMLA JOLLA PHARMACEUTICAL COMPANY ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of LJPC and Encourages Investors to Contact the Firmapnews.com - July 14 at 5:31 PMSHAREHOLDER ALERT: Weiss Law Investigates La Jolla Pharmaceutical Companyprnewswire.com - July 12 at 12:41 AMHow this Peninsula company is turning lung drug royalties into acquisitionsfinance.yahoo.com - July 11 at 8:34 PM Get La Jolla Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for LJPC and its competitors with MarketBeat's FREE daily newsletter. Email Address Only a fool would buy Nvidia today… (Ad)Average people are too busy throwing their money into Nvidia, Google, and every other overvalued tech firm… while missing what could be the biggest story of the decade. In this new presentation – which Porter Stansberry details why this company could be the linchpin of LJPC Media Mentions By Week LJPC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LJPC News Sentiment▼0.000.60▲Average Medical News Sentiment LJPC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LJPC Articles This Week▼10▲LJPC Articles Average Week Get La Jolla Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for LJPC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: DBV Technologies News bluebird bio News X4 Pharmaceuticals News Molecular Partners News Genfit News Sangamo Therapeutics News aTyr Pharma News Cellectis News Zura Bio News Graphite Bio News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LJPC) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceFed launches fourth dollar overhaulStansberry ResearchThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding La Jolla Pharmaceutical Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.